Monday, November 9, 2026

EUR/CHF Went Up By Over 1% In The Last 10 Sessions

ViaNews Editorial Team

August 15, 2024

EUR/CHF Went Up By Over 1% In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.6% for the last 10 sessions. At 12:06 EST on Thursday, 15 August, EUR/CHF (EURCHF) is $0.96.

EUR/CHF's yearly highs and lows, it's 5.98% up from its 52-week low and 3.625% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a positive 0.31%, a negative 0.08%, and a positive 0.30%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.38% (last week), 0.38% (last month), and 0.30% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be oversold (<=20).

News about

  • According to FXStreet on Thursday, 15 August, "On the upside, the USD/JPY pair may encounter immediate resistance at the nine-day Exponential Moving Average (EMA) around the 147.53 level, followed by the 50-day EMA at 153.40 level, with the potential to test the resistance level at 154.50, where previous support has now turned into resistance.", "In terms of support levels, the USD/JPY pair may navigate the region arounda seven-month low of 141.69, reached on August 5. "
  • Usd/jpy consolidates in a familiar rage, holds comfortably above 147.00 mark. According to FXStreet on Thursday, 15 August, "The uncertainty over the likely timing of when the Bank of Japan (BoJ) will hike interest rates again is holding traders back from placing aggressive bets and leading to the USD/JPY pair's range-bound price action. ", "Apart from this, a generally positive risk tone undermines demand for the safe-haven JPY and continues to offer some support to the USD/JPY pair. "
  • According to FXStreet on Tuesday, 13 August, "For support levels, the USD/JPY pair may test a seven-month low at 141.69, recorded on August 5, followed by the throwback support at 140.25.", "On the upside, the USD/JPY pair could test the immediate barrier at the nine-day EMA around the 147.72 level. "
  • Usd/jpy edges higher in a familiar range, retakes 147.00 mark amid risk-on mood. According to FXStreet on Wednesday, 14 August, "Apart from this, expectations that the Bank of Japan (BoJ) will hike rates again in 2024 help limit the JPY losses and might cap the USD/JPY pair.", "This, in turn, will play a key role in influencing the USD demand in the near term and provide some meaningful impetus to the USD/JPY pair. "
  • Usd/jpy trades with mild losses near 147.00 ahead of US PPI data. According to FXStreet on Tuesday, 13 August, "The USD/JPY pair weakens to near 147.10 during the early Asian session on Tuesday. "

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com